Title: 2CARE
Principal Investigator: Francis Walker, M.D.
This double blind study will be to assess the long-term (60 months) efficacy of CoEnzyme Q10 on the progression and functional decline in individuals with Huntington Disease.
Inclusion Criteria:
- Subjects with clinical features of HD and a confirmatory family history of HD or subject with a CAG repeat expansion greater than 36
- Subjects in Stage I or II of illness; subjects must be ambulatory and not requiring skilled nursing care
- Age 18 years or older
- Subjects taking antidepressants and/or neuroleptics must be on stable dosages for at least 4 weeks prior to randomization
- Subjects must be capable of providing informed consent and complying with study procedures
- Subject must be able to take oral medication
- Subject must have family member/caregiver who must be willing to supervise the daily dosing of all study medication to the subject, to maintain control of study medication in the home and to participate in the initial and ongoing consent to participate
Exclusion Criteria:
- History of known sensitivity or intolerance to creatine
- Recent exposure to study drug (creatine)
- Recent exposure to CoEnzyme Q10
- Certain medical conditions as determined by the study physician (investigator)
- History of kidney impairment
- Pregnant women or women currently
Contact: Christine O’Neill
336-716-8611
coneill@wfubmc.edu
Sponsor: National Institutes of Health – Pending